secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2026-03-20T23:59:59+00:00
Accession:  0001214659-26-003620
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum
--------------------------------------------------------------------------------

- Stockholders' equity reported at ~$2.2M as of Jan 31, 2026, below Nasdaq's $2.5M minimum requirement for continued listing.
- Company has until May 4, 2026 to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180 days (to Sept 16, 2026).
- Common stock continues trading on Nasdaq under symbol 'ALZN' with no immediate effect on listing.
- Company is evaluating actions to regain compliance; no assurance plan will be accepted or compliance achieved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926003620/0001214659-26-003620-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465926003620/g3202628k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-26-003620

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer